Valuation: Vaxcyte, Inc.

Capitalization 8.95B 7.6B 7.02B 6.62B 12.28B 833B 12.49B 82.26B 32.24B 401B 33.58B 32.88B 1,425B P/E ratio 2026 *
-8.42x
P/E ratio 2027 * -8.46x
Enterprise value 8.48B 7.2B 6.65B 6.27B 11.63B 789B 11.83B 77.93B 30.54B 380B 31.81B 31.15B 1,350B EV / Sales 2026 *
-
EV / Sales 2027 * 358x
Free-Float
97.87%
Yield 2026 *
-
Yield 2027 * -
1 day+2.89%
1 week+0.83%
Current month+7.04%
1 month+11.83%
3 months+33.51%
6 months+42.69%
Current year+34.81%
1 week 60
Extreme 60
63.27
1 month 52.74
Extreme 52.74
63.27
Current year 43.94
Extreme 43.945
65
1 year 28.09
Extreme 28.09
65
3 years 27.66
Extreme 27.66
121.06
5 years 15.51
Extreme 15.51
121.06
10 years 15.51
Extreme 15.51
121.06
Manager TitleAgeSince
Corporate Officer/Principal 62 26/05/2013
Chief Executive Officer 58 31/10/2013
Director of Finance/CFO 56 30/04/2020
Director TitleAgeSince
Director/Board Member 58 31/10/2013
Director/Board Member 58 30/04/2018
Director/Board Member 56 31/03/2020
Change 5d. change 1-year change 3-years change Capi.($)
+2.89%+0.83%+113.60%+70.41% 8.95B
+0.11%+4.31%+35.71%+101.87% 52.04B
-1.10%-0.50%+101.80%+23.15% 46.83B
-2.69%-10.53%+103.40%+752.48% 30.82B
+2.66%+11.02%+3.94%-21.24% 25.82B
-3.93%-0.50%+74.24%-33.97% 19.66B
+0.24%+0.11%+38.06%-38.31% 17.31B
+1.34%+9.26%+82.04%+245.14% 17.54B
+15.62%+26.46%+5.94%+1,455.41% 18.93B
-0.38%+5.48%+82.20% - 15.56B
Average +1.15%+5.36%+64.09%+283.88% 25.35B
Weighted average by Cap. +0.48%+4.23%+62.65%+252.97%

Financials

2026 *2027 *
Net sales - 23.47M 19.93M 18.4M 17.35M 32.19M 2.18B 32.74M 216M 84.54M 1.05B 88.05M 86.21M 3.74B
Net income -1.12B -952M -879M -829M -1.54B -104B -1.56B -10.3B -4.04B -50.18B -4.21B -4.12B -178B -1.17B -992M -916M -863M -1.6B -109B -1.63B -10.73B -4.21B -52.29B -4.38B -4.29B -186B
Net Debt -472M -401M -370M -349M -647M -43.89B -658M -4.33B -1.7B -21.12B -1.77B -1.73B -75.08B -556M -472M -436M -411M -762M -51.7B -775M -5.11B -2B -24.87B -2.08B -2.04B -88.44B
Logo Vaxcyte, Inc.
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Employees
507
Date Price Change Volume
16/04/26 62.20 $ +2.89% 1,363,830
15/04/26 60.45 $ -3.68% 1,076,329
14/04/26 62.76 $ +1.64% 1,006,558
13/04/26 61.75 $ +1.43% 950,100
10/04/26 60.88 $ -1.31% 863,735
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
62.20USD
Average target price
109.00USD
Spread / Average Target
+75.24%

Quarterly revenue - Rate of surprise